Pharmaceuticals
Innovating to treat disease more effectively
Our global Pharmaceuticals portfolio includes more than 50 key marketed products, many of which are innovative leaders in their therapeutic areas. In 2009 we received a total of 25 positive regulatory decisions in the United States, Europe and Japan.
Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.
Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.
Note that some product links are intended for US residents only.
Learn more about our Pharmaceuticals Division
A-Z
A C D E F G I L M N P R S T V X Z
|
| |
 | Voltaren/Cataflam (diclofenac sodium/potassium)
|
|
| |
 | Certican/Zortress (everolimus)
|
| Lotensin/Cibacen (benazepril hydrochloride)
| |
| Lotensin HCT/Cibadrex (benazepril hydrochloride and hydrochlorothiazide)
| |
 | Clozaril/Leponex (clozapine)
Visit www.clozaril.com (US residents only) |
 | Coartem/Riamet (artemether and lumefantrine)
|
 | Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide)
Visit www.diovan.com (US residents only) |
 | Combipatch/Estalis/Estalis Sequi (estradiol hemihydrate and norethisterone acetate)
|
 | Comtan (entacapone)
Visit www.comtan.com (US residents only) |
 | Cubicin (daptomycin)
|
Pharmaceuticals business at Novartis
Novartis discovers and develops innovative medicines with improved efficacy and fewer side-effects.
Latest news
Patient groups
Our commitment to high-quality healthcare has led to an enduring and trusted partnership between Novartis and various patient groups.
